Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
200 shown of 6,681 total abstracts
  1. Abstract 95202026-06-04 · 20:45 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    H. Rugo, S. Tolaney, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  2. Abstract 49432026-06-03 · 14:45 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-846 study)
    J. Cortes, C. Saura, R. Herbst · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  3. Abstract 98052026-06-05 · 15:15 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    J. Brahmer, E. Winer, G. Curigliano · National Cancer Center Japan
    Oral Abstract SessionMelanoma📄🖼️🎬
  4. Abstract 17942026-06-04 · 20:00 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-132
    S. Modi, F. Andre, S. Antonia, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  5. Abstract 40922026-06-04 · 14:00 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-463
    S. Peters, F. Andre · Royal Marsden Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  6. Abstract 16082026-06-02 · 15:45 CT · E450
    ASCENT-689: Trodelvy (sacituzumab govitecan) 2L in TNBC
    N. Rizvi, M. Krop, G. Curigliano, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  7. Abstract 99602026-06-01 · 16:30 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-117
    S. Modi, H. Borghaei, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  8. Abstract 90572026-06-04 · 14:00 CT · S100A
    Quality of life outcomes with Tagrisso in patients with NSCLC
    H. Borghaei, M. Reck · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  9. Abstract 91732026-06-04 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-920 study)
    G. Curigliano, L. Paz-Ares, J. Brahmer, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  10. Abstract 64092026-06-05 · 21:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with RCC
    L. Paz-Ares, T. Mok, J. Cortes, et al. · National Cancer Center Japan
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  11. Abstract 18292026-06-04 · 19:00 CT · E450
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    M.C. Garassino, N. Rizvi, S. Modi, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  12. Abstract 98542026-06-02 · 19:30 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    S. Modi, C. Saura, G. Curigliano, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  13. Abstract 95022026-06-05 · 19:15 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    M.C. Garassino, M. Reck · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  14. Abstract 11912026-06-04 · 14:15 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for TNBC: KEYNOTE-404
    L. Paz-Ares, R. Herbst, S. Tolaney, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  15. Abstract 49882026-06-05 · 20:45 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with gastric
    H. Borghaei, H. Rugo · MD Anderson Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  16. Abstract 13062026-06-03 · 20:00 CT · S406
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    H. Rugo, J. Brahmer, S. Peters · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  17. Abstract 10352026-06-05 · 18:00 CT · S100A
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-18
    M. Krop, C. Saura, J. Brahmer · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  18. Abstract 44512026-06-01 · 16:00 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-125
    S. Tolaney, L. Paz-Ares · Institut Gustave Roussy
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  19. Abstract 12872026-06-05 · 16:15 CT · Hall B1
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    M.C. Garassino, J. Cortes, L. Paz-Ares, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  20. Abstract 48722026-06-02 · 18:30 CT · Hall B1
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-380
    R. Herbst, G. Curigliano, S. Peters · MD Anderson Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  21. Abstract 91402026-06-05 · 14:30 CT · E450
    Long-term follow-up of Opdivo 3L+ for NSCLC: CheckMate-267
    H. Rugo, J. Cortes, M.C. Garassino, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  22. Abstract 14282026-06-01 · 21:30 CT · S406
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-792
    C. Robert, H. Rugo · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  23. Abstract 10512026-06-04 · 13:30 CT · S406
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-673 study)
    E. Winer, J. Cortes · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  24. Abstract 99112026-06-01 · 21:00 CT · Hall B1
    FLAURA-117: Tagrisso (osimertinib) neoadjuvant in NSCLC
    H. Borghaei, A. Spira, T. Mok · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  25. Abstract 18132026-06-01 · 16:00 CT · S100A
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    G. Curigliano, H. Rugo, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  26. Abstract 10452026-06-02 · 13:00 CT · Hall B1
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    T. Mok, L. Paz-Ares · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  27. Abstract 11192026-06-03 · 19:45 CT · S100A
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    M. Reck, T. Mok, G. Curigliano · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  28. Abstract 41472026-06-01 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-574 study)
    M. Reck, E. Winer, H. Borghaei · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  29. Abstract 48492026-06-03 · 16:15 CT · Arie Crown Theater
    PACIFIC-76: Imfinzi (durvalumab) neoadjuvant in biliary tract
    H. Borghaei, M. Reck, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  30. Abstract 49332026-06-05 · 18:00 CT · E450
    DESTINY-Breast-514: Enhertu (trastuzumab deruxtecan) 1L in gastric
    R. Herbst, S. Modi, L. Paz-Ares, et al. · Institut Gustave Roussy
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  31. Abstract 13582026-06-02 · 20:15 CT · S406
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-638
    G. Curigliano, S. Tolaney, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  32. Abstract 93052026-06-03 · 16:30 CT · S100A
    Quality of life outcomes with Enhertu in patients with NSCLC
    N. Rizvi, H. Borghaei, C. Robert, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  33. Abstract 40562026-06-01 · 21:45 CT · S100A
    Quality of life outcomes with Tecentriq in patients with HCC
    S. Antonia, T. Mok, M. Reck · Dana-Farber Cancer Institute
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  34. Abstract 42152026-06-01 · 14:15 CT · E450
    ASCENT-423: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    S. Modi, J. Cortes · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  35. Abstract 93572026-06-01 · 15:00 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-567 study)
    C. Robert, J. Brahmer, E. Winer · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  36. Abstract 14922026-06-01 · 21:15 CT · S100A
    Long-term follow-up of Keytruda 3L+ for TNBC: KEYNOTE-581
    P. Schmid, S. Modi · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  37. Abstract 42592026-06-04 · 20:15 CT · E450
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    S. Tolaney, M. Krop, C. Saura, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  38. Abstract 14052026-06-02 · 14:15 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-249
    S. Antonia, S. Peters · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  39. Abstract 64102026-06-02 · 13:00 CT · E450
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    A. Spira, C. Robert, M. Krop, et al. · Karolinska Institute
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  40. Abstract 14092026-06-03 · 13:00 CT · S406
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-334
    M.C. Garassino, R. Herbst, N. Rizvi, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  41. Abstract 41302026-06-01 · 13:45 CT · Hall B1
    EV-362: Padcev (enfortumab vedotin) neoadjuvant in urothelial carcinoma
    M. Krop, J. Cortes · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  42. Abstract 55702026-06-04 · 19:00 CT · S100A
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-861 study)
    M.C. Garassino, G. Curigliano, S. Modi, et al. · Royal Marsden Hospital
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  43. Abstract 94372026-06-04 · 16:00 CT · S406
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-284
    S. Modi, M.C. Garassino · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  44. Abstract 90572026-06-05 · 18:15 CT · S406
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-216 study)
    E. Winer, F. Andre, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  45. Abstract 11282026-06-02 · 19:30 CT · Hall B1
    Long-term follow-up of Tecentriq neoadjuvant for TNBC: IMpower-249
    L. Paz-Ares, M.C. Garassino · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  46. Abstract 10922026-06-04 · 21:15 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-424 study)
    E. Winer, F. Andre · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  47. Abstract 14382026-06-02 · 21:00 CT · E450
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    H. Borghaei, N. Rizvi, M. Krop, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  48. Abstract 93872026-06-03 · 16:15 CT · E450
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    S. Modi, M.C. Garassino, C. Saura, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  49. Abstract 10922026-06-05 · 21:30 CT · Hall B1
    MONARCH-362: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    C. Robert, F. Andre, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  50. Abstract 59112026-06-01 · 19:30 CT · S100A
    Long-term follow-up of Lynparza 3L+ for ovarian: OlympiA-245
    E. Winer, G. Curigliano, C. Robert, et al. · Massachusetts General Hospital
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  51. Abstract 18612026-06-01 · 20:15 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-131 study)
    T. Mok, L. Paz-Ares, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  52. Abstract 91702026-06-04 · 20:30 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-544
    A. Spira, G. Curigliano, T. Mok, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  53. Abstract 18572026-06-04 · 15:15 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-977
    C. Robert, T. Mok, M. Krop, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  54. Abstract 93082026-06-05 · 13:00 CT · S100A
    Long-term follow-up of Keytruda 2L for SCLC: KEYNOTE-547
    L. Paz-Ares, M. Krop · Karolinska Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  55. Abstract 94462026-06-02 · 18:00 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-565 study)
    S. Modi, R. Herbst, S. Peters, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  56. Abstract 17422026-06-01 · 21:15 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-9 study)
    C. Robert, S. Antonia, P. Schmid, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  57. Abstract 16142026-06-05 · 14:15 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-747
    T. Mok, H. Rugo, P. Schmid, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  58. Abstract 48622026-06-05 · 21:45 CT · S406
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-420 study)
    A. Spira, S. Tolaney, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  59. Abstract 43092026-06-05 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-878 study)
    P. Schmid, C. Saura, G. Curigliano · Stanford Cancer Institute
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  60. Abstract 44402026-06-04 · 16:00 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with HCC
    N. Rizvi, F. Andre, S. Tolaney, et al. · Massachusetts General Hospital
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  61. Abstract 18152026-06-01 · 21:15 CT · S100A
    IMpower-21: Tecentriq (atezolizumab) 2L in TNBC
    J. Brahmer, S. Antonia · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  62. Abstract 18172026-06-01 · 18:15 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-142
    N. Rizvi, J. Cortes · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  63. Abstract 13442026-06-04 · 19:00 CT · S100A
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-57
    S. Modi, M. Krop, L. Paz-Ares, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  64. Abstract 15922026-06-04 · 18:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-930
    J. Brahmer, F. Andre, S. Tolaney, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  65. Abstract 19402026-06-01 · 21:30 CT · S100A
    MONALEESA-717: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    H. Borghaei, M.C. Garassino, A. Spira, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  66. Abstract 11382026-06-05 · 15:15 CT · E450
    Quality of life outcomes with Keytruda in patients with TNBC
    C. Saura, E. Winer · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  67. Abstract 96722026-06-01 · 21:30 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with NSCLC
    C. Robert, H. Borghaei, A. Spira, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  68. Abstract 19322026-06-03 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-54 study)
    T. Mok, N. Rizvi, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  69. Abstract 92452026-06-01 · 13:30 CT · Hall B1
    PACIFIC-642: Imfinzi (durvalumab) adjuvant in NSCLC
    L. Paz-Ares, F. Andre · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  70. Abstract 97282026-06-04 · 21:00 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with SCLC
    M.C. Garassino, A. Spira, H. Borghaei, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  71. Abstract 15802026-06-02 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-764 study)
    S. Modi, L. Paz-Ares, F. Andre · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  72. Abstract 58492026-06-03 · 18:45 CT · S406
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-44
    C. Saura, J. Cortes, R. Herbst, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  73. Abstract 99242026-06-02 · 15:45 CT · Arie Crown Theater
    KEYNOTE-105: Keytruda (pembrolizumab) adjuvant in NSCLC
    M.C. Garassino, H. Rugo, R. Herbst, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  74. Abstract 11332026-06-04 · 18:00 CT · S406
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-526
    G. Curigliano, S. Antonia, M. Reck, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  75. Abstract 19482026-06-03 · 15:30 CT · Hall B1
    PALOMA-496: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    S. Peters, M. Reck · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  76. Abstract 13252026-06-05 · 16:00 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-74
    T. Mok, M. Reck, A. Spira, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  77. Abstract 46052026-06-05 · 20:00 CT · S100A
    PACIFIC-611: Imfinzi (durvalumab) 2L in biliary tract
    L. Paz-Ares, S. Tolaney, T. Mok, et al. · Cleveland Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  78. Abstract 95782026-06-04 · 20:00 CT · S100A
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-54
    S. Peters, J. Brahmer, H. Borghaei, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  79. Abstract 99332026-06-05 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-893 study)
    R. Herbst, H. Rugo, P. Schmid · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  80. Abstract 93442026-06-04 · 19:30 CT · S406
    DESTINY-Breast-826: Enhertu (trastuzumab deruxtecan) adjuvant in NSCLC
    C. Saura, S. Modi, C. Robert, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  81. Abstract 94522026-06-05 · 15:30 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-544 study)
    S. Modi, C. Robert, J. Brahmer · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  82. Abstract 11412026-06-02 · 13:15 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    S. Antonia, L. Paz-Ares, S. Peters, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  83. Abstract 18132026-06-01 · 18:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-107
    S. Peters, L. Paz-Ares · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  84. Abstract 42352026-06-05 · 13:15 CT · Arie Crown Theater
    Long-term follow-up of Opdivo 2L for HCC: CheckMate-390
    F. Andre, S. Tolaney, P. Schmid, et al. · MD Anderson Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  85. Abstract 69812026-06-02 · 16:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-851
    S. Tolaney, R. Herbst · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  86. Abstract 19442026-06-04 · 20:15 CT · E450
    MONALEESA-619: Kisqali (ribociclib) 1L in HR+ breast cancer
    H. Rugo, M. Reck, S. Peters · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  87. Abstract 41622026-06-01 · 20:45 CT · Hall B1
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    F. Andre, T. Mok, A. Spira · Chinese University of Hong Kong
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  88. Abstract 62362026-06-01 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-390
    J. Cortes, S. Modi, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  89. Abstract 19312026-06-02 · 16:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 1L for HR+ breast cancer: OlympiA-283
    T. Mok, H. Rugo, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  90. Abstract 43952026-06-02 · 16:30 CT · Arie Crown Theater
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    H. Borghaei, J. Cortes, F. Andre · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  91. Abstract 49602026-06-02 · 21:00 CT · Hall B1
    Long-term follow-up of Opdivo neoadjuvant for HCC: CheckMate-788
    T. Mok, S. Antonia, J. Cortes, et al. · National Cancer Center Japan
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  92. Abstract 98472026-06-02 · 20:00 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    N. Rizvi, S. Modi · Peter MacCallum Cancer Centre
    Oral Abstract SessionMelanoma📄🖼️🎬
  93. Abstract 44732026-06-03 · 15:30 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-947
    N. Rizvi, C. Saura, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  94. Abstract 44782026-06-03 · 16:15 CT · S406
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    J. Brahmer, G. Curigliano, M.C. Garassino · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  95. Abstract 10262026-06-04 · 20:00 CT · S100A
    Long-term follow-up of Tecentriq 2L for TNBC: IMpower-898
    A. Spira, H. Borghaei, C. Saura, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  96. Abstract 12922026-06-03 · 13:45 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-780 study)
    J. Brahmer, S. Antonia · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  97. Abstract 47202026-06-03 · 15:30 CT · S406
    Long-term follow-up of Trodelvy adjuvant for urothelial carcinoma: ASCENT-225
    J. Brahmer, A. Spira, S. Antonia, et al. · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  98. Abstract 18022026-06-03 · 19:00 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-664 study)
    S. Modi, S. Tolaney · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  99. Abstract 47972026-06-01 · 19:30 CT · S100A
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-356 study)
    G. Curigliano, C. Robert, F. Andre, et al. · National Cancer Center Japan
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  100. Abstract 94462026-06-03 · 19:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-50 study)
    S. Antonia, M.C. Garassino, M. Reck, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  101. Abstract 18452026-06-03 · 16:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-713 study)
    R. Herbst, C. Saura · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  102. Abstract 44482026-06-03 · 14:15 CT · Hall B1
    Long-term follow-up of Tecentriq maintenance for HCC: IMpower-28
    P. Schmid, C. Saura, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  103. Abstract 92582026-06-05 · 13:30 CT · S406
    FLAURA-725: Tagrisso (osimertinib) maintenance in NSCLC
    G. Curigliano, F. Andre, H. Borghaei, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  104. Abstract 49872026-06-01 · 15:45 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-799
    M. Krop, G. Curigliano, H. Borghaei, et al. · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  105. Abstract 13352026-06-05 · 21:30 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-298 study)
    M. Reck, P. Schmid · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  106. Abstract 12092026-06-03 · 14:30 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with TNBC
    A. Spira, P. Schmid · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  107. Abstract 14332026-06-04 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-855
    E. Winer, F. Andre, J. Cortes, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  108. Abstract 19402026-06-04 · 20:15 CT · S406
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    R. Herbst, M. Krop, J. Brahmer · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  109. Abstract 17342026-06-05 · 20:15 CT · S100A
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-496
    M. Reck, M. Krop, J. Cortes · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  110. Abstract 41162026-06-03 · 13:15 CT · S406
    PACIFIC-87: Imfinzi (durvalumab) neoadjuvant in biliary tract
    H. Rugo, H. Borghaei, L. Paz-Ares · Cleveland Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  111. Abstract 11282026-06-03 · 16:30 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-818
    L. Paz-Ares, S. Peters · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  112. Abstract 17522026-06-04 · 16:30 CT · Hall B1
    PALOMA-808: Ibrance (palbociclib) 1L in HR+ breast cancer
    R. Herbst, M. Krop · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  113. Abstract 11432026-06-03 · 15:00 CT · Hall B1
    Long-term follow-up of Tecentriq 2L for TNBC: IMpower-704
    H. Borghaei, J. Cortes, E. Winer, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  114. Abstract 10972026-06-02 · 21:30 CT · Hall B1
    MONALEESA-639: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    E. Winer, H. Borghaei, R. Herbst, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  115. Abstract 13402026-06-02 · 16:45 CT · E450
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-776
    A. Spira, M. Krop · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  116. Abstract 18962026-06-05 · 19:30 CT · S100A
    DESTINY-Breast-384: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    M. Krop, F. Andre, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  117. Abstract 40872026-06-01 · 19:30 CT · E450
    PACIFIC-136: Imfinzi (durvalumab) maintenance in biliary tract
    L. Paz-Ares, G. Curigliano, J. Cortes, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  118. Abstract 48632026-06-04 · 20:45 CT · S406
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-862 study)
    P. Schmid, C. Saura, R. Herbst · Royal Marsden Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  119. Abstract 19462026-06-03 · 16:30 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-675 study)
    J. Brahmer, H. Rugo · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  120. Abstract 18712026-06-02 · 19:30 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-409
    M. Reck, H. Borghaei, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  121. Abstract 19982026-06-02 · 14:30 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-527 study)
    H. Borghaei, S. Antonia, S. Modi, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  122. Abstract 11162026-06-02 · 20:45 CT · E450
    Long-term follow-up of Tecentriq 3L+ for TNBC: IMpower-333
    L. Paz-Ares, R. Herbst · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  123. Abstract 13632026-06-03 · 19:15 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-675
    R. Herbst, C. Saura, H. Rugo, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  124. Abstract 92612026-06-01 · 20:45 CT · S100A
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-340 study)
    S. Antonia, P. Schmid, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  125. Abstract 15092026-06-04 · 13:30 CT · S406
    Long-term follow-up of Keytruda neoadjuvant for TNBC: KEYNOTE-92
    R. Herbst, F. Andre, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  126. Abstract 94802026-06-04 · 14:30 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-125 study)
    J. Brahmer, G. Curigliano, H. Borghaei, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  127. Abstract 11932026-06-03 · 18:00 CT · E450
    MONALEESA-912: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    T. Mok, E. Winer, H. Rugo, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  128. Abstract 42672026-06-02 · 16:45 CT · Hall B1
    DESTINY-Breast-340: Enhertu (trastuzumab deruxtecan) 2L in gastric
    J. Cortes, S. Antonia · Cleveland Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  129. Abstract 40492026-06-03 · 21:45 CT · E450
    Enhertu plus chemotherapy in previously untreated gastric: updated analysis from DESTINY-Breast-152
    T. Mok, G. Curigliano, S. Peters · Cleveland Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  130. Abstract 103962026-06-04 · 15:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-855 study)
    C. Robert, R. Herbst, E. Winer, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionMelanoma📄🖼️🎬
  131. Abstract 17952026-06-01 · 19:15 CT · Hall B1
    MONARCH-928: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    F. Andre, M. Krop · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  132. Abstract 49162026-06-04 · 14:00 CT · S406
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-485 study)
    T. Mok, J. Cortes, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  133. Abstract 17942026-06-05 · 20:45 CT · Arie Crown Theater
    MONARCH-337: Verzenio (abemaciclib) 2L in HR+ breast cancer
    T. Mok, H. Rugo, M. Krop, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  134. Abstract 99462026-06-03 · 18:15 CT · S406
    Quality of life outcomes with Imfinzi in patients with NSCLC
    H. Borghaei, A. Spira, C. Saura, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  135. Abstract 43182026-06-03 · 16:15 CT · E450
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-806
    H. Borghaei, G. Curigliano, S. Tolaney · Dana-Farber Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  136. Abstract 90252026-06-03 · 21:30 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-529
    L. Paz-Ares, M. Krop, F. Andre, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  137. Abstract 41052026-06-01 · 18:30 CT · S406
    ASCENT-940: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    L. Paz-Ares, G. Curigliano, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  138. Abstract 49782026-06-04 · 13:15 CT · Hall B1
    EV-139: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    E. Winer, J. Brahmer, T. Mok, et al. · MD Anderson Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  139. Abstract 96562026-06-03 · 15:15 CT · E450
    FLAURA-887: Tagrisso (osimertinib) 2L in NSCLC
    H. Borghaei, G. Curigliano, C. Robert · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  140. Abstract 16892026-06-03 · 15:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-373 study)
    P. Schmid, C. Saura, M.C. Garassino, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  141. Abstract 10092026-06-03 · 13:00 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-27
    H. Borghaei, H. Rugo, J. Cortes, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  142. Abstract 96002026-06-01 · 18:15 CT · Hall B1
    Long-term follow-up of Enhertu 3L+ for NSCLC: DESTINY-Breast-810
    S. Tolaney, F. Andre · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  143. Abstract 11172026-06-02 · 14:15 CT · S100A
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-760
    M.C. Garassino, F. Andre, C. Robert, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  144. Abstract 18642026-06-05 · 16:30 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-241
    N. Rizvi, C. Saura, F. Andre, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  145. Abstract 10052026-06-04 · 14:15 CT · E450
    PALOMA-189: Ibrance (palbociclib) maintenance in HR+ breast cancer
    P. Schmid, C. Robert · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  146. Abstract 96602026-06-05 · 15:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-195 study)
    H. Rugo, C. Saura, M. Reck · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  147. Abstract 12862026-06-05 · 16:30 CT · S406
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-596
    P. Schmid, S. Peters, T. Mok, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  148. Abstract 92452026-06-03 · 21:30 CT · S406
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-842
    C. Saura, J. Brahmer, L. Paz-Ares, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  149. Abstract 49662026-06-02 · 20:00 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    S. Peters, L. Paz-Ares, C. Saura, et al. · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  150. Abstract 101922026-06-03 · 18:45 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    G. Curigliano, A. Spira · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  151. Abstract 16642026-06-01 · 14:45 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    S. Modi, J. Cortes, C. Robert, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  152. Abstract 45252026-06-01 · 14:00 CT · S100A
    Long-term follow-up of Trodelvy neoadjuvant for urothelial carcinoma: ASCENT-969
    J. Cortes, A. Spira, S. Peters, et al. · Mayo Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  153. Abstract 95992026-06-02 · 13:15 CT · E450
    Long-term follow-up of Tecentriq adjuvant for NSCLC: IMpower-170
    H. Borghaei, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  154. Abstract 49882026-06-02 · 13:45 CT · S100A
    Long-term follow-up of Imfinzi maintenance for biliary tract: PACIFIC-800
    F. Andre, L. Paz-Ares · Mayo Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  155. Abstract 43852026-06-01 · 21:30 CT · S406
    EV-336: Padcev (enfortumab vedotin) neoadjuvant in urothelial carcinoma
    R. Herbst, S. Peters, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  156. Abstract 46982026-06-03 · 15:15 CT · S406
    Long-term follow-up of Tecentriq 3L+ for HCC: IMpower-291
    M.C. Garassino, L. Paz-Ares, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  157. Abstract 91362026-06-03 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-190 study)
    P. Schmid, T. Mok · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  158. Abstract 99952026-06-02 · 19:00 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-808 study)
    F. Andre, G. Curigliano, R. Herbst, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  159. Abstract 41412026-06-05 · 13:00 CT · Arie Crown Theater
    Quality of life outcomes with Imfinzi in patients with biliary tract
    E. Winer, M.C. Garassino, G. Curigliano · Mayo Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  160. Abstract 90212026-06-04 · 19:00 CT · Hall B1
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-143
    R. Herbst, S. Antonia, T. Mok, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  161. Abstract 11432026-06-03 · 19:30 CT · Arie Crown Theater
    PALOMA-846: Ibrance (palbociclib) 1L in HR+ breast cancer
    M. Krop, T. Mok · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  162. Abstract 13092026-06-01 · 13:30 CT · E450
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-364
    C. Saura, H. Borghaei, S. Peters, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  163. Abstract 11822026-06-05 · 21:15 CT · S406
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-302
    T. Mok, G. Curigliano, J. Cortes, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  164. Abstract 10072026-06-04 · 21:45 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-716
    R. Herbst, N. Rizvi, H. Rugo, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  165. Abstract 67752026-06-05 · 19:15 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-537 study)
    F. Andre, R. Herbst, J. Cortes · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  166. Abstract 99742026-06-01 · 18:45 CT · E450
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    P. Schmid, G. Curigliano · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  167. Abstract 12762026-06-04 · 20:45 CT · S100A
    PALOMA-174: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    A. Spira, S. Antonia, N. Rizvi · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  168. Abstract 69522026-06-05 · 18:15 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in RCC
    F. Andre, S. Tolaney, C. Robert, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  169. Abstract 49802026-06-03 · 15:15 CT · S406
    EV-441: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    L. Paz-Ares, M. Reck · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  170. Abstract 66062026-06-04 · 20:45 CT · Hall B1
    KEYNOTE-77: Keytruda (pembrolizumab) neoadjuvant in RCC
    F. Andre, C. Saura, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  171. Abstract 99612026-06-04 · 15:45 CT · S406
    FLAURA-437: Tagrisso (osimertinib) 1L in NSCLC
    C. Saura, M. Reck, G. Curigliano, et al. · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  172. Abstract 41702026-06-05 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-637
    S. Tolaney, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  173. Abstract 95822026-06-02 · 20:00 CT · E450
    IMpower-197: Tecentriq (atezolizumab) neoadjuvant in NSCLC
    E. Winer, P. Schmid, S. Peters, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  174. Abstract 41402026-06-01 · 19:30 CT · Hall B1
    EV-636: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    M. Krop, T. Mok, H. Rugo · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  175. Abstract 44802026-06-02 · 19:15 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-752 study)
    H. Borghaei, P. Schmid, E. Winer, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  176. Abstract 18242026-06-04 · 20:45 CT · S406
    PALOMA-545: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    P. Schmid, R. Herbst · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  177. Abstract 67252026-06-03 · 13:15 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-864
    S. Antonia, J. Cortes · Chinese University of Hong Kong
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  178. Abstract 16702026-06-01 · 20:45 CT · S100A
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-540
    C. Saura, R. Herbst, N. Rizvi · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  179. Abstract 12302026-06-04 · 14:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-692
    M. Krop, S. Modi, G. Curigliano, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  180. Abstract 95842026-06-02 · 13:15 CT · S406
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-885
    L. Paz-Ares, S. Peters, M.C. Garassino, et al. · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  181. Abstract 11842026-06-04 · 15:45 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-31
    S. Peters, N. Rizvi · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  182. Abstract 91472026-06-04 · 13:00 CT · S100A
    PACIFIC-739: Imfinzi (durvalumab) adjuvant in NSCLC
    T. Mok, E. Winer, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  183. Abstract 10762026-06-02 · 19:45 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    S. Tolaney, S. Modi, G. Curigliano, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  184. Abstract 43192026-06-04 · 15:30 CT · S406
    ASCENT-667: Trodelvy (sacituzumab govitecan) maintenance in urothelial carcinoma
    J. Brahmer, J. Cortes · University of Chicago
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  185. Abstract 10002026-06-03 · 20:15 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-764 study)
    H. Borghaei, S. Tolaney · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  186. Abstract 56172026-06-01 · 13:30 CT · S100A
    Long-term follow-up of Lynparza adjuvant for prostate: OlympiA-692
    C. Robert, H. Rugo · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  187. Abstract 91572026-06-04 · 18:00 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    R. Herbst, H. Borghaei, S. Tolaney, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  188. Abstract 19852026-06-01 · 14:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-987
    E. Winer, M.C. Garassino, S. Tolaney · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  189. Abstract 16412026-06-04 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-93 study)
    E. Winer, S. Antonia, C. Robert · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  190. Abstract 98342026-06-01 · 19:30 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    P. Schmid, J. Cortes, M. Reck, et al. · Stanford Cancer Institute
    Oral Abstract SessionMelanoma📄🖼️🎬
  191. Abstract 101272026-06-01 · 18:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-492 study)
    A. Spira, M.C. Garassino · Royal Marsden Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  192. Abstract 15752026-06-01 · 14:00 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-389 study)
    M. Krop, R. Herbst, S. Peters, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  193. Abstract 95712026-06-04 · 18:00 CT · S406
    FLAURA-339: Tagrisso (osimertinib) neoadjuvant in NSCLC
    J. Cortes, M. Krop · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  194. Abstract 91542026-06-04 · 13:30 CT · Arie Crown Theater
    KEYNOTE-145: Keytruda (pembrolizumab) adjuvant in SCLC
    E. Winer, S. Tolaney · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  195. Abstract 18132026-06-03 · 15:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-754 study)
    J. Cortes, G. Curigliano, S. Peters · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  196. Abstract 15192026-06-04 · 20:00 CT · S406
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-73
    S. Modi, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  197. Abstract 16752026-06-03 · 14:30 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    M. Krop, M.C. Garassino · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  198. Abstract 92892026-06-03 · 14:15 CT · Hall B1
    FLAURA-288: Tagrisso (osimertinib) 2L in NSCLC
    C. Saura, T. Mok, H. Borghaei, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  199. Abstract 94272026-06-03 · 15:30 CT · E450
    CheckMate-520: Opdivo (nivolumab) 3L+ in NSCLC
    S. Tolaney, J. Brahmer, S. Antonia, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  200. Abstract 48222026-06-04 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-761 study)
    H. Rugo, E. Winer, S. Peters, et al. · Royal Marsden Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.